



Celsion Corporation
Investor Relations Department
997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: CLSN

Last Trade:	1.56
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.03 ↑ (+1.961%)
Day Range	1.52 - 1.56
52-Week Range	1.24 - 17.93
Volume	158,111

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celsion Corporation is an oncology drug development company focused on the development of efficient, effective, and targeted therapies for the treatment of cancer. Founded in 1985, the company has developed elegant therapeutic approaches that deliver high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the side-effects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications. The foundation for this research is a heat-sensitive liposomal nanoparticle licensed from Duke Universit... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 24, 2017 [Celsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference](#)
- Aug 15, 2017 [Celsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update](#)
- Aug 8, 2017 [Celsion Corporation to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 15, 2017](#)
- Aug 7, 2017 [Data Monitoring Committee Completes Mid-Study Review of Celsion's Phase III ThermoDox® OPTIMA Study in Primary Liver Cancer](#)
- Aug 4, 2017 [Celsion Corporation to Delist from the Tel Aviv Stock Exchange](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 24, 2017 [Annual Report \(10-K\)](#)
- Apr 4, 2017 [Proxy Statement \(DEF 14A\)](#)
- Aug 14, 2017 [Quarterly Report \(10-Q\)](#)
- May 12, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 10, 2016 [Quarterly Report \(10-Q\)](#)